Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barbara Giomarelli is active.

Publication


Featured researches published by Barbara Giomarelli.


Structure | 2006

Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding.

Natasza E. Ziółkowska; Barry R. O'Keefe; Toshiyuki Mori; Charles Zhu; Barbara Giomarelli; Fakhrieh S. Vojdani; Kenneth E. Palmer; James B. McMahon; Alexander Wlodawer

Summary The crystal structure of griffithsin, an antiviral lectin from the red alga Griffithsia sp., was solved and refined at 1.3 Å resolution for the free protein and 0.94 Å for a complex with mannose. Griffithsin molecules form a domain-swapped dimer, in which two β strands of one molecule complete a β prism consisting of three four-stranded sheets, with an approximate 3-fold axis, of another molecule. The structure of each monomer bears close resemblance to jacalin-related lectins, but its dimeric structure is unique. The structures of complexes of griffithsin with mannose and N-acetylglucosamine defined the locations of three almost identical carbohydrate binding sites on each monomer. We have also shown that griffithsin is a potent inhibitor of the coronavirus responsible for severe acute respiratory syndrome (SARS). Antiviral potency of griffithsin is likely due to the presence of multiple, similar sugar binding sites that provide redundant attachment points for complex carbohydrate molecules present on viral envelopes.


AIDS | 2002

The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1

Barbara Giomarelli; Roberta Provvedi; Francesca Meacci; Tiziana Maggi; Donata Medaglini; Gianni Pozzi; Toshiyuki Mori; James B. McMahon; Roberta S. Gardella; Michael R. Boyd

ObjectiveTo explore the feasibility of expressing the potent HIV-inactivating protein, cyanovirin-N (CV-N), in the human commensal bacterium Streptococcus gordonii, as a possible approach for local delivery of CV-N to prevent sexual transmission of HIV-1. Design and methodsTo express CV-N in S. gordonii, we used the host-vector system we had previously developed. CV-N was expressed as a fusion protein both attached to the bacterial surface and secreted in soluble form in the supernatant of liquid cultures. The soluble form of recombinant CV-N was tested for gp120-binding activity in an enzyme-linked immunosorbent assay, whereas S. gordonii strain expressing CV-N on the surface was analyzed in an in vitro HIV capturing assay. ResultsTwo recombinant S. gordonii strains secreting or displaying CV-N on the bacterial surface were constructed and the expression of CV-N was confirmed by immunoblot and flow-cytometric analysis. The secreted form of recombinant CV-N exhibited a concentration-dependent binding to the envelope glycoprotein gp120 of HIV-1, whereas CV-N displayed on the bacterial surface was able to capture HIV virions efficiently. ConclusionThe anti-HIV protein CV-N in S. gordonii was expressed in a biologically active form. This represents a first step in the development of a system to deliver and maintain an effective concentration of a microbicide in the vaginal mucosa.


Vaccine | 2008

Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA.

Annalisa Ciabattini; Barbara Giomarelli; Riccardo Parigi; Damiana Chiavolini; Elena Pettini; Beatrice Aricò; Marzia Monica Giuliani; Laura Santini; Donata Medaglini; Gianni Pozzi

NadA and NhhA, two surface proteins of serogroup B Neisseria meningitidis identified as candidate vaccine antigens, were expressed on the surface of the human oral commensal bacterium Streptococcus gordonii. Recombinant strains were used to immunize BALB/c mice by the intranasal route and the local and systemic immune response was assessed. Mice were inoculated with recombinant bacteria administered alone or with LTR72, a partially inactivated mutant of Escherichia coli heat-labile enterotoxin, as a mucosal adjuvant. Intranasal immunization with live bacteria expressing NadA induced a significant serum antibody response, with a prevalence of the IgG2a subclass, bactericidal activity in the sera of 71% of animals, and a NadA-specific IgA response in nasal and bronchoalveolar lavages. A formalin-inactivated recombinant strain of S. gordonii expressing NadA was also administered intranasally, inducing a systemic and mucosal humoral response comparable to that of live bacteria. The administration of recombinant bacteria with the mucosal adjuvant LTR72 stimulated a stronger systemic antibody response, protective in 85% of sera, while did not increase the local IgA response. Recombinant S. gordonii expressing NhhA induced a systemic but not mucosal antibody response. These data support the role of NadA as vaccine candidate against serogroup B meningococci, and the use of S. gordonii as vector for intranasal vaccination.


Cryptogamie Mycologie | 1999

Lichens and mosses as biomonitors of trace elements in a geothermal area (Mt. Amiata, central Italy)

Stefano Loppi; Barbara Giomarelli; Roberto Bargagli

Abstract The effectiveness of epiphytic lichens (Parmelia sulcata) and epigeic mosses (Hypnum cupressiforme) as passive monitors of trace elements released by geothermal power plants was evaluated in the Mt. Amiata area (central Italy). The results showed that despite concentrations of most elements (Al, As, Fe, Hg, Pb, Sb, Zn) being higher in lichens than in mosses, both organisms can be used as effective biomonitors of elements of geothermal concern (As, Hg, Sb).


Thrombosis and Haemostasis | 2007

Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-1

Barbara Giomarelli; Valance Washington; Maia M. Chisholm; Laura Quigley; James B. McMahon; Toshiyuki Mori; Daniel W. McVicar

TREM-like transcript-1 (TLT-1) is a novel platelet membrane receptor, which has been recently characterized in mice. TLT-1 is expressed exclusively in platelets and megakaryocytes, and its expression is dramatically upregulated upon platelet activation, suggesting that it plays a unique role in hemostasis and/or thrombosis. In this study we identified and characterized highly specific human monoclonal antibodies that bind to TLT-1 by screening a naïve library of single chain Fv fragments (scFvs) displayed on filamentous phage (Thomlinson I library). These scFvs detected plate-bound TLT-1, captured soluble TLT-1, and readily reacted with cell-bound TLT-1 on transfectants and primary human platelets. Most importantly, anti-TLT-1 scFvs inhibited thrombin-mediated human platelet aggregation. This inhibition was specific for thrombin-induced aggregation and was reversible with higher doses of agonist. These data are the first to demonstrate a biological role for TLT-1 and its potential as a therapeutic target. The human scFvs isolated in this study may represent novel anti-platelet therapeutic agents.


Molecular Biotechnology | 2004

Expression of a functional single-chain Fv antibody on the Surface of Streptococcus gordonii

Barbara Giomarelli; Tiziana Maggi; Justine Younson; Charles Kelly; Gianni Pozzi

Gram-positive bacterium Streptococcus gordonii, a human oral commensal, was engineered to display a single-chain Fv (scFv) antibody fragment at the cell surface. The previously developed host-vector system allowed expression of the Guys 13 scFv as a fusion with the streptococcal surface protein M6. Surface expression of the 515-amino acid M6/scFv fusion protein was confirmed by Western blot analysis on cellular fractions and flow cytometric analysis. Guys 13 scFv was derived from the Guys 13 monoclonal antibody, which was raised against streptococcal antigen I/II (SA I/II), the major adhesin of the caries-producing bacterium Streptococcus mutans. Surface plasmon resonance was used to test binding of scFv-expressing S. gordonii to SA I/II. Whole cells of recombinant S. gordonii were found to specifically bind to immobilised SA I/II and binding was inhibited by fluid-phase SA I/II in a dose-dependent manner. Production of a functional scFv in S. gordonii is the first step towards the development of genetically engineered commensal bacteria that, by colonizing mucosal surfaces, may provide the host with sustained delivery of recombinant antibodies.


Structure | 2010

Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity.

Tinoush Moulaei; Shilpa R. Shenoy; Barbara Giomarelli; Cheryl L. Thomas; James B. McMahon; Zbigniew Dauter; Barry R. O'Keefe; Alexander Wlodawer


Protein Expression and Purification | 2006

Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture.

Barbara Giomarelli; Kathryn M. Schumacher; Troy E. Taylor; Raymond C. Sowder; James L. Hartley; James B. McMahon; Toshiyuki Mori


Fems Microbiology Letters | 2006

Binding of Streptococcus gordonii to extracellular matrix proteins.

Barbara Giomarelli; Livia Visai; Karolin Hijazi; Simonetta Rindi; Michela Ponzio; Francesco Iannelli; Pietro Speziale; Gianni Pozzi


Archive | 2006

Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions

Toshiyuki Mori; Daniel W. McVicar; Barbara Giomarelli; A. V. Washington

Collaboration


Dive into the Barbara Giomarelli's collaboration.

Top Co-Authors

Avatar

Toshiyuki Mori

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James B. McMahon

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel W. McVicar

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Alexander Wlodawer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Barry R. O'Keefe

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michael R. Boyd

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge